Table 2.
FDA-approved PARPi class drugs.
| PARP inhibitors | FDA-approved cancers | Year of approval |
|---|---|---|
| Olaparib | Advanced ovarian cancer | 2014 |
| Primary peritoneal cancer | 2017 | |
| HER-2 negative metastatic breast cancer | 2018 | |
| Metastatic pancreatic adenocarcinoma | 2019 | |
| Metastatic castration-resistant prostate cancer(mCRPC) | 2020 | |
| Rucaparib | Ovarian cancer | 2016 |
| Recurrent epithelial ovarian | 2018 | |
| Primary peritoneal cancer | ||
| Metastatic castration-resistant prostate cancer(mCRPC) | 2020 | |
| Niraparib | Primary peritoneal cancer | 2017 |
| Advanced ovarian | 2019 | |
| Primary peritoneal cancer | ||
| Talazoparib | HER-2 negative locally advanced or metastatic breast cancer | 2018 |